Upadacitinib Improves Ulcerative Colitis Outcomes at 12 Months
Risk for composite outcome was lower, including lower risks for intravenous steroid use and colectomy, within 12 months in sensitivity analysis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.